ANZCTR search results

Despite the substantial volume of bifurcation PCI which is performed in ANZ, there is no local registry in which procedural techniques, device usage, and outcomes are documented. The study is observational in nature only, with PCI selection and technique will be left at the discretion of the operator. Eligible subjects will be enrolled into the registry after providing informed consent. Medical records review and phone call follow up will be performed to assess for the incidence of the primary and secondary outcome at 72hrs (medical record only), 3 months, 1 year and 2 years.

The purpose of this study is to develop and test a transitional model of care coordination to optimally support people living with multimorbidity, post-hospital discharge, via telehealth, and ensure continuity of care between the secondary (acute) and primary healthcare sectors to minimise direct contact with hospital services. The intervention will be a 6-8 week care coordination support from 'STARnurses' for 6 -8 weeks post-hospital discharge. We hypothesise that the provision of a transition support service, post-hospital discharge, for patients with multimorbidity will decrease the short-term hospital readmission rate for that patient cohort.

This is an investigational combination treatment arm within the ALLG AMLM26 INTERCEPT trial platform, which is registered on ANZCTR with ID ACTRN12621000439842. This treatment arm (Ivosidenib + Venetoclax) will be evaluated for its activity in a population of participants with progressive acute myeloid leukemia (AML). Who is it for? You may be eligible for to receive this treatment if you are a part of the AMLM26 Intercept trial which is registered on ANZCTR with ID ACTRN12621000439842 (ie if you are aged 18 or older, you have been diagnosed with progressive acute myeloid leukemia, and are currently in your first or second morphologic remission with a known and trackable minimal residual disease (MRD) marker.). If you are on the AMLM26 Intercept trial you may be eligible for this treatment option if your disease is worsening. The trial management committee will review your disease characteristics and determine your best treatment option(s) available on the trial. Study details Ivosidenib and Venetoclax are given orally. Ivosidenib 500mg once a day commencing day 15 of cycle one and taken continuously and Venetoclax administered days 1-14 of a 28 day cycle for 12 cycles. Patients with minimal residual disease will have a pilot safety run-in phase to confirm dose - investigating Venetoclax doses 800mg or 600mg daily. Once a tolerable dose is determined that dose will be used in a proof of concept phase.. Patients with morphologic relapse will enter directly into a proof of concept phase using a Venetoclax dose of 800mg daily with a dose ramp up in cycle 1. Participants will undergo a disease assessment at screening after cycle 1, cycle 2, cycle 3, cycle 6 and then 2 monthly until progression. This will require blood tests and bone marrow biopsies. Safety and tolerability of treatment will be assessed throughout the trial whilst you are receiving treatment. Health related quality of life during treatment will be assessed on the first treatment day of 3 consecutive cycles. This study is being carried out to improve the way we treat cancer patients who may have limited treatment options available to them. It is hoped that Ivosidenib and Venetoclax will be well tolerated and may improve outcomes for future patients, however, there may be no clear benefit from participation in this study.

Examining all intubated patients presenting with drug overdose to GCHHS EDs. Retrospective cohort study. Descriptive. Low risk from ethics perspective. Data collection from Feb 2021 to Sept 2023.

The Powerful Pictures study is an ambitious project which seeks to partner with First Nations Australians to co-design a new, improved model of care to identify and manage heart disease in patients at risk of future heart attacks. This model of care includes increasing access to a high-quality imaging test, Computed Tomography Coronary Angiography (CTCA) for the detection of early heart disease. The Powerful Pictures model of care will be co-designed with local communities, patients with lived experience of a possible heart attack, local clinicians, health workers, and health services managers and leadership. The model will then be implemented in regional (Cairns), outer regional (Atherton and Mareeba) and remote (Weipa) hospitals across Far North Queensland

The aim of this study is to address the knowledge gaps relating to prehabilitation in older frail patients having hip or knee surgery, and to explore the opportunities of delivering home-based preoperative care through digital technology. Patients will be randomly allocated to a treatment group. One group will receive standard preoperative care before their surgery. The other group will receive standard care plus the prehabilitation program before their surgery. This study also acts to inform future research in frail patients undergoing these surgeries to optimise post-operative outcomes.

Gemini is being developed as a potential new drug as a treatment for reducing the incidence, duration, and severity of acute kidney injury following cardiac surgery and for surgical site infection. The purpose of this research study is to evaluate safety, tolerability, how the body uses the drug and how the drug affects the body in healthy participants. The study drug works by stimulating a protein called toll-like receptor, which plays an important role in activating the natural immune response. The immune system is the body's first line of defence against invaders such as viruses, bacteria, parasites or toxins entering the body, or to detect wounds in trauma.

Psychotic illness tends to emerge during adolescence, which is a stage of critical social development. One of the earliest signs of psychotic illness is social difficulties, which can cause young people to become withdrawn from everyday life. Psychotic symptoms like paranoia and hallucinations (hearing or seeing things that aren’t there) can make it hard for young people to function around others. These symptoms are usually triggered in social situations, which can make young people want to avoid them, ultimately making the problem worse and causing them to become more withdrawn. Psychological treatments like cognitive behavioural therapy can be effective for helping young people feel comfortable in social situations. However, these treatments are delivered in clinics, removed from the social situations where they need the most help, and are therefore have limited effectiveness. Virtual reality (VR) is a technology that involves wearing a headset which projects 3D images of real world environments onto a screen so the user feels like they are immersed in that environment. Users can interact with the virtual environment using hand controllers, and virtual characters (‘avatars’) are often present to simulate social interactions. Research has found that VR can be used to support treatment of social difficulties by guiding people to learn and practice social skills in virtual environments. This technology therefore has potential to help young people who experience symptoms of psychosis, which is yet to be explored. This research aims to evaluate a new VR treatment based on cognitive behavioural therapy for young people experiencing hallucinations (a common and distressing symptom of psychosis) to understand whether it is feasible and safe to deliver, and whether it has potential to improve social functioning.

The aim is to use Artificial Intelligence based tools for automated measurement of lesions/areas of ischemia in stroke patients. This data will be used for patient outcome prediction.

Australia has the highest prevalence of food allergy in the world, with at least one in every 32 (3.1%) infants developing peanut allergy and one in every 66 (1.5%) infants developing a cashew nut allergy, which are usually lifelong. Nut allergies place individuals and their families under enormous stress and have been shown to decrease quality of life. This trial aims to determine if the risk of developing peanut and cashew nut allergy during infancy can be reduced by a maternal diet rich in peanuts and cashew nuts during breastfeeding. A finding from our recent Western Australian pilot randomised controlled trial (ACTRN12617001465347) with 109 mother-infant pairs discovered that a maternal high-peanut diet, compared to a low-peanut diet, during the first six months of lactation may reduce the risk that her infant will develop a peanut allergy. We now propose a definitive efficacy randomised controlled trial, in order to provide high-quality evidence to inform maternal diet guidelines for peanut and cashew nut allergy prevention. If the hypothesis is correct, this will be a simple strategy to reduce nut allergies. If incorrect, this information will be paramount for informing breastfeeding women about food choices. Participating mothers will be randomly allocated into either a high-nut (minimum of 60 peanuts and 40 cashew nuts per week), or a low-nut (maximum of 20 peanuts and 12 cashew nuts per week) group, for 6 months from the birth of their baby. From six months of age after commencement of solid foods, both groups will be encouraged to include smooth peanut butter and cashew nut spread in their baby’s diet as per our current Australian infant feeding and allergy prevention guidelines. Infant peanut and cashew nut allergy outcomes will be assessed during infancy. This trial has been co-designed with consumers who will continue to be involved in all stages.